ALGO Falls 5.72% as Investor Focus Shifts to E-Commerce and Biotech Updates

On November 20, 2025, the value of

dropped by 5.72% in a single day, reaching $0.1447, amid ongoing market volatility. Over the previous week, the token declined by 12.29%, saw a 19.11% decrease over the past month, and experienced a steep 57.1% fall in the last year. This downward trend mirrors the general lack of immediate growth drivers within the ALGO ecosystem, even as related industries remain active.

Allegro Delivers Mixed Results in E-Commerce

Allegro, Poland’s top e-commerce company, posted robust third-quarter results domestically, with revenue rising 17.2% year-over-year to 1.04 billion zlotys, beating market forecasts. The growth was attributed to lower shipping expenses, higher advertising income, and strong performance from its consumer lending division. Nevertheless, Allegro revised its 2025 gross merchandise value (GMV) outlook downward, pointing to weaker-than-anticipated demand at the start of winter. While the company’s main business remained strong, missed earnings abroad and the updated forecast led investors to be more cautious.

Argo Graphene Shares Positive Concrete Test Outcomes

At the same time, Argo Graphene Solutions revealed favorable results from a 28-day compressive strength assessment of its graphene-enhanced concrete in Tennessee. The material showed an 11% increase in compressive strength compared to the standard 4,000 psi design, confirming earlier university research. CEO Scott Smale commented that these findings support the company’s expectations and indicate potential for broader market adoption. Although this progress is promising for Argo’s materials division, it does not have a direct effect on ALGO or the cryptocurrency sector.

Alvotech Under Pressure After Guidance Revision

Elsewhere, biotech company Alvotech came under scrutiny from investors after sharply lowering its 2025 revenue and adjusted EBITDA projections. The company referenced a complete response letter from the FDA regarding its main biosimilar product, AVT05, which cited ongoing manufacturing issues. Shareholder group Hagens Berman has launched an investigation into possible disclosure problems. The announcement led to a 33% plunge in Alvotech’s share price, though it did not have a direct impact on ALGO’s valuation.

ALGO Market Outlook

Despite notable updates in e-commerce, construction, and biotech, none of these stories are directly connected to ALGO’s core technology or network activity. The token’s persistent decline seems to mirror broader market caution, risk-averse trading, and the lack of a clear short-term driver. Experts anticipate that ALGO’s price will likely remain within its current range until a significant on-chain or ecosystem event occurs. In the meantime, investors are expected to keep an eye on macroeconomic trends and industry-specific news for any signs of a turnaround.